Company News » Amneal Signs Deal to Acquire the Generic Business of Actavis AustraliaBusiness Wire - March 31, 2015, 00:35 GMT
Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, a subsidiary of Actavis plc (NYSE:ACT) , today announced they have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis’ in-country generic pharmaceuticals business for an agreed price, subject to completion of confirmatory due diligence and definitive agreements.
Actavis plc (NYSE:ACT) today announced that it has completed the acquisition of Allergan, Inc. (NYSE:AGN) in a cash and equity transaction valued at approximately $70.5 billion. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in
Company News » European Commission Clears Actavis’ Pending Acquisition of AllerganBusiness Wire - March 16, 2015, 14:27 GMT
March 16, 2015–Actavis plc (NYSE:ACT) (“Actavis”) and Allergan, Inc. (NYSE:AGN) (“Allergan”) today announced that the companies received clearance from the European Commission for Actavis’ pending acquisition of Allergan. Clearance by the European Commission satisfies the final regulatory condition to the closing of the pending acquisition, which remains subject to certain customary closing conditions